Healthcare shortages power Covista, regulation tests it
- Covista trains nurses, doctors, veterinarians, and other health workers through five schools.
- Walden remains the fastest grower, ending FY26 with enrollment up 14.0% to 54,851 students.
- Chamberlain has continued to recover, with Q4 enrollment growth accelerating to 1.6%.
- The biggest outside risk is federal education policy, especially student loan access after OBBBA.
- The next proof points are Sallie Mae financing, fall Chamberlain demand, and new campus launches.
Shortage tailwind, policy overhang
Covista sits in a large labor problem. The U.S. needs more healthcare workers, and Covista runs schools that train them. That gives the company a real demand tailwind if students can pay, pass, and find jobs.
The bull case has improved with FY26 results. Walden is still compounding, with Q4 enrollment up 14.0% to 54,851 students. Chamberlain turnaround is gaining momentum, accelerating to 1.6% enrollment growth in Q4. Adjusted earnings power shows strong operating leverage.
The bear case is still serious. Covista is a proprietary school operator, which means it makes money from tuition and has long depended on federal student aid rules. The One Big Beautiful Bill Act creates Do No Harm provisions. This establishes an earnings-based accountability framework that could threaten program eligibility. Covista is working with Sallie Mae on alternative financing.
Two open questions matter. Management has not shared the specific economics of the SSM Health partnership, so investors do not yet know how profitable that model can be. Capital spending is also expected to step up materially as a proxy for 2027 campus expansion.
Tuition tied to healthcare jobs
Covista makes money by charging tuition for degree and certificate programs. Its main schools are Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine.
The model works best when three things line up: student demand, available financing, and good career outcomes. Chamberlain is tied closely to nursing demand. Walden serves many working adults online. The medical and veterinary schools serve students seeking professional degrees.
Covista is also connecting its capacity directly to employers. The SSM Health partnership is an example. It is meant to fund education, add clinical experience, and create a hiring path. That could make Covista more useful to hospitals, but the profit details are still not public.
The model can break if students cannot finance tuition, if enrollment teams miss intake cycles, or if regulators tighten rules on aid, accreditation, or student outcomes. Those risks are not distant, given the new OBBBA Do No Harm provisions.
Schools inside the platform
Chamberlain University
Chamberlain is the nursing and health professions engine. In FY26 it produced $750.2 million of revenue, up 3.4%, and total enrollment growth returned to 1.6% in Q4.
Walden University
Walden serves many working adults online across nursing, education, counseling, business, psychology, and social work. Q4 FY26 enrollment rose 14.0%, making it the clearest growth engine with $804.9 million in FY26 revenue.
Medical schools, AUC and RUSM
American University of the Caribbean School of Medicine and Ross University School of Medicine train future doctors. They sit in the Medical and Veterinary segment.
Ross University School of Veterinary Medicine
RUSVM gives Covista exposure to veterinary education. It adds another professional degree path inside the same student financing and accreditation risk frame.
AI credentials
Covista launched AI credentials across nursing, medicine, and foundational AI. More certificates are planned in veterinary medicine, mental health, and other fields.
Employer partnerships
Programs like SSM Health aim to link education funding, clinical experience, and hiring. This could become a stronger sales channel if the economics prove attractive.
Three revenue engines
The mix uses FY26 full-year segment revenue: Walden at $804.9 million, Chamberlain at $750.2 million, and Medical and Veterinary at $398.9 million.
What could go wrong
OBBBA Do No Harm framework
High impact · Medium oddsOBBBA established an earnings-based accountability framework. A program may lose Title IV eligibility if completer earnings do not exceed high school diploma or bachelor's degree baselines. If enforced, certain programs could lose federal aid.
Student financing gap
High impact · Medium oddsOBBBA changed federal student loan access. Covista is working with Sallie Mae on an alternative loan syndicate. If that syndicate is delayed, students may have trouble paying for programs.
Campus expansion costs run ahead of returns
Medium impact · Medium oddsManagement expected capital spending to step up in Q4 as a proxy for 2027. The company plans 6 new Chamberlain campuses. If new campuses fill slowly, spending could rise before revenue catches up.
Employer partnership economics stay unclear
Medium impact · Low oddsThe SSM Health partnership supports the story that Covista can connect schools to employers. Management has not shared specific economics. Without those details, investors cannot tell whether the model is a high-return channel or mainly a branding win.
In one breath
What does Covista do?
Covista runs healthcare-focused schools in the U.S. Its programs train nurses, doctors, veterinarians, social workers, counselors, and other health workers.
Why did Adtalem become Covista?
Management said the new name reflects a single platform for healthcare workforce development. The rebrand became part of the Q3 FY26 story.
What is the main growth driver for Covista?
Walden is the clearest current growth driver, with Q4 FY26 enrollment up 14.0%. Chamberlain adds more upside as its enrollment recovery continues.
What is OBBBA, and why does it matter to Covista?
OBBBA introduced Do No Harm provisions measuring program earnings against baselines. That matters because programs failing the test could lose Title IV federal student aid eligibility.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- September 13, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
